This study seeks to understand the safety of a gene editing therapy called CRISPR_SCD001 and if this treatment can help people with severe sickle cell disease get better.
The RISE UP Study seeks to determine if an investigational molecule called “mitapivat” has the potential to improve the health of red blood cells in individuals living with sickle cell disease by improving the energy and reducing the sickling of red blood cells.
>
16 years or older
YearsSCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
3
This study, conducted by Lance Archer, a doctoral student in the School of Psychology at Fielding Graduate University, Santa Barbara, CA, aims to understand why some adults with sickle cell disease (SCD) may have difficulties taking Hydroxyurea medication.
This study aims to understand why some SCT carriers are at higher risk for Exercise Collapse Associated with Sickle Cell Trait (ECAST).
This study is being conducted by Sickle Cell 101 to understand our sickle cell and global community’s thoughts on sickle cell trait, genotype awareness, and educational gaps associated with the evolving research about potential complications of sickle cell trait.
Hemoglobin levels in people living with sickle cell disease are typically lower than the average person.
>
18
YearsSCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
2
“The Electronic Patient Reported Pain Assessment in Sickle Cell” study aims to gather insights into painful crises in people living with sickle cell disease.
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.
